Combination of Ranibizumab and Targeted Laser Photocoagulation

This study is testing a combination treatment for macular edema caused by central retinal vein occlusion (CRVO) — a condition where a vein in the retina becomes blocked, causing fluid to build up in the central part of the eye (the macula) and blurring vision. The treatment being studied combines ranibizumab (an anti-VEGF injection that reduces fluid) with targeted laser treatment to damaged areas of the retina. Researchers want to see if this combined approach is better than using the injection alone, potentially reducing how many injections patients need over time while preserving or improving vision. You may be eligible if: - You are over 18 years old - You have macular edema due to central retinal vein occlusion (CRVO) diagnosed within the last 6 months - Your retinal thickness (foveal) exceeds 250 micrometers on OCT imaging - Your vision in the affected eye falls within a certain range (24–78 letters on the ETDRS chart) - You have significant areas of poor blood flow in the peripheral retina You may NOT be eligible if: - Your CRVO has caused damage to the central blood vessel network of the macula (ischemic maculopathy) - Your macular edema has another cause (e.g., diabetes, uveitis, macular degeneration) - You have previously used anti-VEGF injections in the study eye - You have had eye surgery, laser treatment, or steroid injections in the study eye recently - You have had a stroke or heart attack in the past 3 months - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.